Investment, Funding & Disinvestments

CereVasc designed the facility to meet the company’s expected operational needs as it advances the eShunt System towards potential commercialisation.

The divestment forms part of the company’s broader restructuring as it seeks to strengthen its finances and sharpen its focus on higher-value healthcare products.

IMPACT Therapeutics received approval from China’s National Medical Products Administration (NMPA) in January 2025 for senaparib as a first-line maintenance therapy for adults with advanced ovarian, fallopian tube, or primary peritoneal cancer.

AbCellera will oversee discovery and early-stage development activities, while Vertex will finance all research and development costs.

BYPHAR is designed to simplify raw material selection while helping manufacturers meet increasingly stringent quality and regulatory requirements throughout the development and production process.

Under the agreement, the companies will advance Sail’s lead programme, SAIL-0839, which is being developed to engineer CD4+ and CD8+ T-cells inside the body to treat immune-mediated diseases.

The acquisition follows Novartis AG’s decision in 2024 to review the future of its India-listed subsidiary.

The investment will upgrade Resilience’s manufacturing operations in Ohio, where the company has produced Lilly’s Mounjaro and Zepbound since the partners began working together in 2023.

The initiative comes as scientists intensify efforts to address a major Bundibugyo ebolavirus outbreak, with cases rising rapidly in the Democratic Republic of the Congo (DRC).

Under the proposed PPP structure, the Egyptian-Turkish consortium will oversee the project’s construction and non-medical operations.